Mumbai, May 7 -- The revenue growth was largely driven by growth in global generics revenues in North America as well as Emerging Markets.

Consolidated profit before tax stood at Rs 1,601.6 crore during the March 2024 quarter, up 20.83% YoY.

EBITDA grew 14.77% to Rs 1,872 crore in Q4 FY24 as against Rs 1,631.1 crore recorded in the corresponding quarter previous year. EBITDA margin improved to 26.4% in Q4 FY24 as against 25.9% posted in Q4 FY23.

Q3 FY24 gross margin stood at 58.6%, up 140 bps YoY, primarily on account of improvement in product mix and productivity cost savings, partially offset by income from non-core brands divested in previous period.

Selling, general & administrative (SG&A) expenses for Q4 FY24 were at Rs 2,047.6 c...